Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve(TM) Antimicrobial Wound Gel
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(75)
•••
Comment by francoisl13on Aug 22, 2024 9:52am
42 Views
Post# 36191570

RE:New Press Release - Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve(TM) Antimicrobial Wound Gel

RE:New Press Release - Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve(TM) Antimicrobial Wound GelInteresting news, according to their website, Razan Medical & Surgical Equipment (RMT) is involved in the whole MENA region. The UAE ppulation is only 9,8 millions but the MENA region as a population of around 500 millions (according to the 'World Bank Group'...
This region is considered a young, dynamic one with a rapid growth rate with most of the population having an intermediate revenue (not define in the article I've read).
This could develop as an interesting deal if RMT can execute in the whole region not only UAE.
GLTA!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities